



Therapeutic Area Oncology

Ongoing: 62 studies with 20,587 patients

1 Lung Cancer

Afatinib as first-line treatment compared to standard first-line chemotherapy in NSCLC patients with EGF receptor mutations

Nintedanib in combination with docetaxel in the second-line therapy of patients with advanced NSCLC

Afatinib as adjuvant therapy in unresected locally advanced HNSCC (Asia)

8 Ovarian Cancer

Nintedanib in combination with paclitaxel/carboplatin in the first-line treatment of patients with advanced ovarian cancer

12 Colorectal Cancer

Nintedanib vs placebo in patients with colorectal cancer refractory to standard treatments

9 Head and Neck Cancer

Afatinib in recurrent/advanced head and neck squamous cell carcinoma (HNSCC)

10 Leukaemia

Volasertib in combination with low-dose cytarabine in patients < 65 years with previously untreated AML, who are ineligible for intensive therapy

Therapeutic Area Respiratory

Ongoing: 12 studies with 11,675 patients

1 COPD

Effect of 52 weeks of once daily treatment of orally inhaled tiotropium/olodaterol Respimat\* compared to each monotherapy

Efficacy & safety of tiotropium/olodaterol Respimat\* compared to each monotherapy

1 Idiopathic pulmonary fibrosis

Nintedanib in patients with Idiopathic Pulmonary Fibrosis

Open Label Extension Study to INPULSIS

1 Asthma

Tiotropium in adult patients with severe asthma

Tiotropium in adult patients with mild asthma

Tiotropium in adolescent patients with severe asthma

Therapeutic Area Central Nervous System

Ongoing: 6 studies with 2,436 patients

BI 409306 in patients with cognitive impairment in schizophrenia

BI 409306 in patients with prodromal Alzheimer's Dementia

BI 409306 in patients with Alzheimer's Dementia

Therapeutic Area Immunology and Inflammation

Ongoing: 9 studies with 2,835 patients

Dose-finding trial in Psoriasis. Head-to-head comparison to ustekinumab (Stelara)

PoCC and dose-finding trial in Ankylosing Spondylitis

BI695501 compared to adalimumab in patients with active rheumatoid arthritis


Clinical Activities at Boehringer Ingelheim in Numbers

During the past decade from 2005 to 2014, Boehringer Ingelheim conducted or sponsored 1,414 studies with 115 substances in 95 countries from all regions of the world.

The studies enrolled nearly 1 Million patients during this decade, of which about 390,000 were in phase I-IV studies and over 600,000 in NIS (non-interventional) and other study types.

Table with columns: Study type, Number of protocols, Region, I-III, IV, NIS/Other\*

\*The category 'Other' includes, for example, compassionate use, expanded access programs, named patient use programs, epidemiological studies and methodological studies.



6 Prevention of mother-to-child transmission (MTCT) of HIV

Prevention of mother-to-child transmission of HIV (pMTCT) including breastfeeding studies and resistance issues

Therapeutic Area Cardiometabolic

Ongoing: 23 studies with 61,328 patients

4 Diabetes

Cardiovascular safety of TRAJENTA\* or glimepiride in patients with high CV risk

Head-to-head study comparing TRAJENTA\* with a SU\*

JARDIANCE\*/TRAJENTA\* FDC\* factorial design US registration study

Cardiovascular safety and Renal Microvascular Endpoints of TRAJENTA\* in subjects with type 2 diabetes mellitus

TRAJENTA\* and metformin versus glimepiride + metformin

JARDIANCE\*/TRAJENTA\* FDC\* filter design EU registration study

Efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease

JARDIANCE\* in patients with cardiovascular risk

JARDIANCE\*/TRAJENTA\* FDC\* filter design EU registration study

Avoiding hypoglycemia in the Elderly (>70 years), with LINagliptin

JARDIANCE\* vs placebo, MDI insulin background

JARDIANCE\* + metformin vs individual monotherapies

5 Myocardial infarction

Early fibrinolysis in STEMI patients (3 hours of onset) followed by catheterisation within 6-24 hours or rescue intervention versus primary PCI\*

7 1 Deep vein thrombosis and pulmonary embolism

Treatment of acute venous thromboembolism

Secondary prevention of venous thromboembolism

Secondary prevention of venous thromboembolism

2 Stroke

Stroke prevention in atrial fibrillation

RE-LY\* Study of stroke prevention in atrial fibrillation

Stroke prevention in atrial fibrillation in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting

Global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation

RE-DUAL PCI\* A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate

Characterization of newly diagnosed patients with non-valvular atrial fibrillation at risk for stroke, and to study patterns, predictors and outcomes of different treatment regimens for stroke prevention

RE-VERSE AD\* Study of reversal effects of Idarucizumab on Active Dabigatran trial

Secondary Stroke prevention in patients with embolic stroke of undetermined source (ESUS)

RE-SPECT ESUS\* Randomized, double-blind evaluation in secondary stroke prevention comparing the efficacy and safety of the thrombin inhibitor dabigatran etexilate